LVAD an underutilized advanced heart failure treatment.
Nearly three-quarters of systematic reviews published in high-impact cardiology journals over the past decade achieved “low” or “critically low” scores on the AMSTAR quality tool, a new analysis finds.
Instituting electronic medical record-based appointment orders can significantly increase outpatient cardiology follow-up visits after hospital discharge, but it doesn’t necessarily lower 30-day readmissions.
A review of recent major cardiovascular medicine studies reveals that only 1 in 10 first authors, senior authors and trial leadership committee members are women.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Check out this numeric portrait of a few of Cleveland Clinic’s interventional and electrophysiologic procedural offerings from the year just passed.
From heart benefits of diabetes drugs to leadless pacing to expanding populations for TAVR, 2016 was a dynamic year in cardiovascular care. Cleveland Clinic experts reflect on a dozen key developments.
Our series of infographics profiling the nation’s No. 1 heart program turns to cardiovascular medicine. Here’s the lowdown on some key recent outcomes and volumes.
FDA’s late-July approval of the first PCSK9 inhibitor is “a major event in cardiovascular medicine,” says Dr. Steve Nissen. Here’s his expert take on the place of this new cholesterol-lowering class in today’s practice.